瑞舒伐他汀联合非诺贝特对老年糖尿病视网膜病变患者血管内皮功能的影响

doi:10.6040/j.issn.1673-3770.0.2015.142

摘要/Abstract

摘要： 目的分析瑞舒伐他汀联合非诺贝特治疗老年糖尿病视网膜病变患者时,对血清单核细胞趋化因子-1(MCP-1)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)水平的影响。方法选择糖尿病视网膜病变患者140例,按入院先后顺序,以随机数字表法将患者分为瑞舒伐他汀组(单药组)和瑞舒伐他汀与非诺贝特联合治疗组(联合组)各70例。二组患者性别、年龄、体质量、血脂、血压及糖化血红蛋白水平差异无统计学意义(P>0.05)。单药组给予瑞舒伐他汀钙10 mg/d,联合组在单药组基础上给予非诺贝特胶囊100 mg/次,3次/d,观察时间为3个月。治疗前与治疗后晨空腹抽取肘静脉血,酶联免疫吸附法检测血清单核细胞趋化因子-1(MCP-1)、基质金属蛋白酶-9(MMP-9)及血管内皮生长因子(VEGF)水平的变化。结果单药组患者治疗后与治疗前比较, MCP-1[(2.59±0.38)比(3.23±0.61)μg/L,t=2.697]、MMP-9[(47.47±5.13)比(69.38±6.28)ng/L,t=2.868]、VEGF[(125.48±8.27)比(198.47±12.63)ng/L,t=2.846];联合组患者治疗后与治疗前比较, MCP-1[1.14±0.29)比(3.17±0.53)μg/L,t=3.217]、MMP-9[(34.18±4.29)比(71.05±7.36)ng/L,t=3.163]、VEGF[(87.39±10.27)比(195.28±11.49)ng/L,t=3.352],二组患者上述指标治疗后明显减少,差异有统计学意义(P<0.05)。其中,治疗后联合组MCP-1、MMP-9、VEGF水平较单纯组减少更为显著,差异有统计学意义(P<0.05)。结论瑞舒伐他汀钙与非诺贝特联合治疗有助于维持老年糖尿病视网膜病变患者血管内皮细胞功能稳定。

关键词: 瑞舒伐他汀钙, 糖尿病视网膜病变, 基质金属蛋白酶-9, 单核细胞趋化因子-1, 血管内皮生长因子

Abstract: Objective To investigate the effects of rosuvastatin combined with fenofibrate therapy on monocyte chemotactic factor-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor (VEGF) in elderly diabetic patients with retinopathy. Methods A total of 140 cases with diabetic retinopathy admitted during Oct. 2012 and Oct. 2014 were randomly divided into rosuvastatin group (single drug group, n=70), and rosuvastatin and fenofibrate treatment group (combined group, n=70). The single drug group received rosuvastatin calcium 10 mg/d, while the combined group were given rosuvastatin calcium 10mg/d, and Fenofibrate Capsules 100 mg once for 3 times each day. The clinical baseline levels of sex, age, body weight index, blood lipid, blood pressure and andglycated hemoglobin in the two groups had no significant differences (P<0.05). The changes of MCP-1, MMP-9 and VEGF before and after treatment were compared. Results The levels of MCP-1, MMP-9 and VEGF in the single drug group were [(2.59±0.38) vs (3.23±0.61) μg/L,t=2.697], [(47.47±5.13) vs (69.38±6.28) ng/L, t=2.868], [(125.48±8.27) vs (198.47±12.63) ng/L, t=2.846], while the levels of MCP-1, MMP-9 and VEGF in the combined group were [(1.14±0.29) vs (3.17±0.53) μg/L, t=3.217], [(34.18±4.29) vs (71.05±7.36) ng/L, t=3.163], [(87.39±10.27) vs (195.28±11.49) ng/L, t=3.352], before and after treatment, respectively. The indexes in the two groups significantly reduced after treatment. The levels of MCP-1, MMP-9 and VEGF in combined group reduced more significantly than in the single drug group, and the difference was statistically significant (P<0.05). Conclusion Rosuvastatin calcium and fenofibrate treatment contributes to the stable endothelial function in elderly diabetic retinopathy patients.

Key words: Endothelial function, Matrix metalloproteinase-9, Vascular endothelial growth factor, Diabetic retinopathy, Monocyte hemotactic factor-1

中图分类号:

R774.1

李俊英. 瑞舒伐他汀联合非诺贝特对老年糖尿病视网膜病变患者血管内皮功能的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(5): 72-75.

LI Junying. Effects of rosuvastatin combined with fenofibrate therapy on vascular endothelial function retinopathy diabetic retinopathy patients[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(5): 72-75.

参考文献

[1] 郑志. 糖尿病视网膜病变临床防治:进展、挑战与展望[J]. 中华眼底病杂志, 2012, 28(3):209-212. ZHENG Zhi. Clinical prevention and treatment of diabetic retinopathy: progress, challenges and prospects[J]. Chin J Ocul Fundus Dis, 2012, 28(3):209-212.
[2] 王月欣, 陈松. 糖尿病视网膜病变神经损伤的发病机制和保护防治研究进展[J]. 中华眼底病杂志, 2014, 30(2):209-211. WANG Yuexin, CHEN Song. Research progress and protection of diabetic retinopathy in the pathogenesis[J]. Chin J Ocul Fundus Dis, 2014, 30(2):209-211.
[3] 朱鸿, 朱耀春, 胡海林, 等. 糖尿病视网膜病变相关临床和生物化学指标的检测和预警意义[J]. 中华眼底病杂志, 2012, 28(3):219-223. ZHU Hong, ZHU Yaochun, HU Hailin, et al. Detection and early warning significance of clinical and biochemical parameters in diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2012, 28(3): 219-223.
[4] 谢安明, 王雅君, 崔丽君. 血管内皮祖细胞与VEGF对增生性糖尿病视网膜病变新生血管形成的影响[J]. 西安交通大学学报:医学版, 2013, 34(2):233-235. XIE Anming, WAGN Yajun, CUI Lijun, et al. Effect of vascular endothelial progenitor cells and VEGF on angiogenesis in proliferative diabetic retinopathy[J]. J Xi'an Jiao Tong University: Med Edition, 2013, 34(2): 233-235.
[5] 李建军, 糖尿病视网膜病变诊断及治疗建议[J]. 眼科, 2005, 14(4): 24-26. LI Jianjun. Diagnosis and treatment of diabetic retinopathy[J]. Ophthalmol, 2005, 14(4):24-26.
[6] 杨继玲, 邵毅, 裴重刚. 调脂药治疗糖尿病视网膜病变的研究进展[J]. 中华眼底病杂志, 2014, 30(2):216-218. YANG Jiling, SHAO Yi, PEI Chonggang. Progress in the treatment of diabetic retinopathy by lipid profile[J]. Chin J Ocul Fundus Dis, 2014, 30(2):216-218.
[7] 祝伟, 苏冠方, 王晨光, 等. 糖尿病视网膜病变的病理机制和新型药物研究进展[J]. 中国老年学杂志, 2013, 33(3): 1206-1209. ZHU Wei, SU Guanfang, WANG Chenguang, et al. Research progress of pathological mechanism and new drugs for diabetic retinopathy[J]. Chin J Gerontol, 2013, 33(3):1206-1209.
[8] Ceraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-dalta and SHP-1 by hyperglycemia causes cascular cell apoptosis and diabetic retinopathy[J]. Nat Med, 2009, 15(11):1298-1306.
[9] Kim J H, Yu Y S. Blockade of angiotensin II attenuates VEGF-mediated blood retinal barrier breakdown in diabetic retinopathy[J].J Cerebr Blood F Met, 2009, 29(3):621-628.
[10] Adamiec-Mroczek J, Oficjalska-Mlynczak J, Misiuk-Hojlo M. Proliferative diabetic retinopathy the influence of diabetes control on the activation of the intraocular molecule system[J]. Didbetes Res Clin Pract, 2009, 84(1):46-50.

相关文章 15

[1]	李浩,李延忠,王岩. HIF-1α、VEGF在阻塞性睡眠呼吸暂停低通气综合征患者[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 43-47.
[2]	周学义,李一鸣,王美菊,张苑苑,张历浊. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89.
[3]	王翠,颜昕,赵博军. IVR联合PDT治疗湿性年龄相关性黄斑变性的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 94-97.
[4]	周玮琰,王洪亚,杜秀娟,董卫红. 甘糖酯对糖尿病大鼠视网膜病变中血管生成因子VEGF表达的影响[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 90-95.
[5]	邵娜,张晗. 糖尿病患者行白内障超声乳化术后视力及眼底的变化[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 83-87.
[6]	李盈盈, 周涵, 张伟强, 董伟达. 沉默HIF-1α基因对鼻黏膜上皮细胞生长因子表达的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(5): 38-42.
[7]	杜祥阁, 张营春, 颜昕, 王翠, 赵博军. 下调血管内皮细胞蛋白激酶CK2表达对血管增殖影响的体外研究[J]. 山东大学耳鼻喉眼学报, 2015, 29(3): 76-80.
[8]	张营春, 杜祥阁, 颜昕, 王翠, 赵博军. 尼古丁对人RPE细胞及HUVEC的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(2): 74-80.
[9]	刘志高, 颜世龙, 胡尊霞, 孙同鑫, 杨明, 王玉. 济南市农村白内障患者糖尿病及糖尿病视网膜眼底病变患病率调查分析[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 38-39.
[10]	马栋, 郭承伟. 络治法对STZ诱导的糖尿病大鼠视网膜血管消化铺片中VCAM-1表达的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 64-68.
[11]	刘海洋, 李甦雁, 张正培, 范巍. 改良膜分割与双手膜清除技术在23G玻璃体手术治疗增殖性糖尿病视网膜病变中的对比[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 52-55.
[12]	刘蓓1,朱忠桥1,杜善双1,王丽丽2,杨新光1. 前期激光及曲安奈德应用对增殖性糖尿病视网膜病变玻璃体切割手术的影响[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 66-68.
[13]	谢丽综述，魏伟审校. 糖尿病性黄斑水肿的治疗进展[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 81-85.
[14]	李俐华，任基浩, 殷团芳，刘伟. 儿童复发性呼吸道乳头状瘤组织中STAT3、VEGF的表达及微血管密度测定与复发、侵袭的关系[J]. 山东大学耳鼻喉眼学报, 2011, 25(6): 11-.
[15]	王淑雅，华宁，李筱荣 . 糖尿病性盲患者玻璃体手术后的脱盲率及未脱盲原因分析 [J]. 山东大学耳鼻喉眼学报, 2011, 25(6): 77-79.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed